Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection-Reference-Cited by-同舟云学术

Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection

Published:2020-07 Issue: Volume:145 Page:181-185
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Pertejo-Fernandez Ana,Ricciuti Biagio,Hammond Sarah P.,Marty Francisco M.,Recondo Gonzalo,Rangachari Deepa,Costa Daniel B.,Awad Mark M.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference10 articles.

1. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

3. Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis;Kothapalli;Melanoma Res.,2018

4. Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non–small cell lung cancer;Ostios-Garcia;J. Thorac. Oncol.,2018

5. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection;Tio;Eur. J. Cancer,2018

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis;Liver International;2024-08-29

2. Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors;Journal of Immunotherapy and Precision Oncology;2024-05-01

3. Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B;Cancer;2024-01-02

4. The Missed Opportunity: HIV, Hepatitis C Virus (HCV), and Hepatitis B Virus (HBV) Positive Patients in Neoadjuvant and Perioperative Immunotherapy Clinical Trials for Lung Cancer;Cureus;2023-12-29

5. Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research;Clinical Genitourinary Cancer;2023-12